CNS-directed gene therapy for lysosomal storage diseases

Area of Science:

• Neuroscience
• Genetics
• Metabolic Disorders

Background:

• Lysosomal storage diseases (LSDs) are inherited metabolic disorders often impacting the central nervous system (CNS).
• Conventional treatments like bone marrow transplantation (BMT) and enzyme replacement therapy (ERT) show limitations in addressing CNS manifestations of LSDs.

Purpose of the Study:

• To explore gene therapy as a potential treatment for CNS involvement in LSDs.
• To evaluate methods for enhancing enzyme distribution and efficacy within the CNS.

Main Methods:

• Direct intracranial injection of viral gene transfer vectors in animal models of LSDs.
• Utilizing protein transduction domains (PTDs) to enhance enzyme delivery.
• Investigating anterograde and retrograde axonal transport for widespread brain distribution.
• Exploring combination therapies, including BMT and CNS-directed gene therapy.

Main Results:

• Gene therapy vectors demonstrated reduced lysosomal storage and functional improvements in animal models.
• PTDs increased enzyme distribution and correction extent.
• Axonal transport facilitated delivery of therapeutic enzymes to distant brain sites.
• Combination therapies showed increased efficacy in refractory CNS LSD cases.

Conclusions:

• Development of persistent gene transfer vectors is crucial.
• Protein transduction domains (PTDs) enhance enzyme delivery.
• Understanding enzyme trafficking and combining therapies offer hope for treating CNS LSDs.